Evelo Biosciences Inc
NASDAQ:EVLO
Intrinsic Value
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. [ Read More ]
The intrinsic value of one
EVLO
stock under the Base Case scenario is
0.995
USD.
Compared to the current market price of 0.046 USD,
Evelo Biosciences Inc
is
Undervalued by 95%.
Evelo Biosciences Inc's market capitalization is 869.4k USD.
EVLO stock price is 0.046 USD.
EVLO stock price (0.046 USD) is 95% less than its Intrinsic Value (0.995 USD).
EVLO. Open Relative Valuation
EVLO.
EVLO has negative Free Cash Flow for the last twelve months.
EVLO has negative Operating Income for the last twelve months.
EVLO has negative Net Income for the last twelve months.
EVLO's ROE (Return on Equity) has significantly increased in the last 3 years from -156% to 946%.
EVLO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -373% to -817%, and is approaching profitability.
EVLO's ROE (Return on Equity) for the past 12 months is very high and is equal to 946%.
EVLO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -817%.
EVLO's short-term liabilties (40m USD) exceed its short-term assets (19m USD).
EVLO's long-term liabilties (47m USD) exceed its long-term assets (21m USD).
EVLO has negative three-year average ROE (Return on Equity): -429%. The company is not efficient at transforming stockholders' equity into net income.
EVLO has negative three-year average ROIC (Return on Invested Capital): -611%. The company is not efficient at using invested capital to generate operating income.
EVLO's D/E (Debt to Equity) is very low and is equal to 0.
EVLO's Altman Z-Score is very low and is equal to -53.15.
EVLO doesn't generate enough operating income (-74m USD) to safely cover interest payments on its debt (5m USD).
Fundamental Analysis
Evelo Biosciences Inc
Balance Sheet Decomposition
Evelo Biosciences Inc
| Current Assets | 18.9m |
| Cash & Short-Term Investments | 17.3m |
| Other Current Assets | 1.6m |
| Non-Current Assets | 1.7m |
| PP&E | 900k |
| Other Non-Current Assets | 800k |
| Current Liabilities | 39.8m |
| Accounts Payable | 500k |
| Accrued Liabilities | 4.6m |
| Other Current Liabilities | 34.7m |
| Non-Current Liabilities | 7.5m |
| Other Non-Current Liabilities | 7.5m |
Earnings Waterfall
Evelo Biosciences Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-74.3m
USD
|
|
Operating Income
|
-74.3m
USD
|
|
Other Expenses
|
-8m
USD
|
|
Net Income
|
-82.3m
USD
|
Free Cash Flow Analysis
Evelo Biosciences Inc
What is Free Cash Flow?
EVLO Profitability Score
Profitability Due Diligence
Evelo Biosciences Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Evelo Biosciences Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
EVLO Solvency Score
Solvency Due Diligence
Evelo Biosciences Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Score
Evelo Biosciences Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EVLO Price Targets Summary
Evelo Biosciences Inc
Ownership
EVLO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
EVLO Price
Evelo Biosciences Inc
| Average Annual Return | 10.75% |
| Standard Deviation of Annual Returns | 139.18% |
| Max Drawdown | -100% |
| Market Capitalization | 869.4k USD |
| Shares Outstanding | 17 384 200 |
| Percentage of Shares Shorted | 2.22% |
Company Profile
Evelo Biosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-05-09. The firm is focused on discovering and developing an orally delivered investigational medicines that acts on cells in the small intestine to produce therapeutic effects throughout the body. The company has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are orally delivered pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles. Its product candidate, EDP1815, is being developed for the treatment of inflammatory diseases. Its other product candidates in development include EDP1867 and EDP2939 for the treatment of inflammatory disease. The company has developed an integrated platform namely, SINTAX Medicine Platform, which is designed to identify individual strains of microbes capable of modulating the immune system by acting on SINTAX when administered at pharmacologically active doses and appropriately formulated.
You don't have any saved screeners yet
